President Trump announced his intention last month to peg U.S. drug prices to those that foreign governments have set within their borders.
The very same day, federal officials said they’d reveal in February 2026 a list of 15 drugs subject to price controls through Medicare’s Part B outpatient benefit and Part D prescription drug benefit starting in 2028.
The widespread embrace of price controls in Washington is bad news for patients.
